Newborn common genetic disease gene detection kit and application thereof
By designing neonatal gene mutation detection kits and high-throughput sequencing technology, gene capture probes are optimized, and the problem of limited detection range in the existing technology is solved, and efficient and convenient screening of neonatal hereditary diseases is achieved. Clinical diagnosis and intervention.
Patent Information
- Application Number
- CN202411142224.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-12
AI Technical Summary
The existing genetic testing technology for neonatal genetic diseases has limited coverage and cannot detect multiple gene variants at the same time, resulting in a lack of efficient and convenient early diagnosis and intervention methods in clinical practice.
A neonatal gene mutation detection kit is designed, which contains a set of probes that specifically capture target genes. Combined with high-throughput sequencing technology, gene capture probes can be optimized, and gene capture probes can be detected simultaneously by multiple neonatal hereditary disease pathogenic genes. Provide a wide coverage of testing solutions.
It has achieved efficient, convenient and low-cost screening of neonatal hereditary diseases, significantly reducing the rate of genetic defects, and assisting clinical diagnosis and intervention.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of genetics, and more specifically to a gene detection kit for common genetic diseases in newborns and applications thereof. Background Art
[0003] Early screening and early detection of congenital birth defects are the best prevention and treatment methods.
[0004] Common neonatal genetic diseases such as genetic metabolism-related neonatal jaundice, neonatal convulsions and neonatal diabetes will directly affect the survival and later growth quality of the child, and even lead to neonatal death. Through the consensus of experts from various countries and the recommended screening of neonatal genetic diseases, 2160 diseases involving 1355 genes are included in the scope of neonatal screening. As genome sequencing technology has gradually entered the clinic and has been successfully applied to neonatal screening, it can not only determine the diagnosis of a disease as soon as possible, but also help discover new causes of the disease, which will help with early clinical diagnosis, intervention and treatment, and reduce birth defects in the region.
[0005] With the rapid development of gene sequencing technology, the widespread development of genetic screening for genetic diseases and related clinical research, genetic screening for neonatal diseases has shown good prospects for the prevention, diagnosis, treatment and rehabilitation of children's diseases. In routine neonatal screening, an NBSeq project uses genetic testing as a second-order screening, which significantly reduces the false positive rate of initial screening. At the same time, it can provide confirmation information and disease typing information for true positive cases, and guide clinical diagnosis and treatment strategies in a timely and effective manner. However, the genetic disease screening kits currently reported for diagnosis, intervention or prevention in the neonatal period cover a small number of newborn genetic diseases, and there are few technologies that can detect multiple gene mutations at the same time. Therefore, there is an urgent need for a rapid genetic detection method for newborn genetic diseases with a wide coverage and simple operation in clinical practice. Summary of the invention
[0006] In order to make up for the above-mentioned defects in the existing genetic detection technology for neonatal genetic diseases, the inventors have developed a new neonatal gene mutation detection kit, which has a wide gene coverage, high sensitivity, good specificity and high throughput, and can significantly reduce the genetic defect rate of neonates. It will help in early clinical diagnosis, intervention and treatment, and prevent newborns from suffering from genetic diseases.
[0007] Solutions for solving problems
[0008] On the one hand, the present invention provides a probe set for detecting gene mutations of common genetic diseases in newborns, wherein the probe set is a probe composition for specifically capturing target gene sequences, and the target genes include one or more of ACADM, SMPD1, TYR, PAH, ACADS, GJB2, ATP7B, UBE3A, DUOX2, HEXA, HBA2, HBA1, MEFV, PMM2, KRT14, G6PC1, GAA, SRD5A2, GALM, FANCL, SUCLG1, PJVK, STK4, NCF4, CRTAP, COL7A1, MCCC1, IL7R, SMN2, SMN1, NKX2-5, PROP1, TUBB2B, ALDH5A1, CYP21A2, MMUT, PHIP, SNX10, GCK, PSPH, SLC26A4, CFTR, TPK1, FGFR1, EYA1, TAF2, FANCC and FKTN.
[0009] Preferably, the GC content of each probe in the probe composition is 40% to 60%.
[0010] Preferably, the annealing temperature of each probe in the probe composition is 65°C to 75°C.
[0011] Preferably, the nucleotide sequence of the probe composition is shown in SEQ ID NO: 1 to SEQ ID NO: 581.
[0012] In one aspect, the present invention provides a detection reagent, comprising any one of the probe sets described above.
[0013] On the one hand, the present invention provides a kit for detecting gene mutations of common genetic diseases in newborns, the kit comprising a target gene sequence capture component, and the target gene sequence capture component comprises any one of the probe sets described above.
[0014] Preferably, in the target gene sequence capture component, the concentration of each probe is 0.5 to 15 μM, preferably 0.5 to 10 μM.
[0015] Preferably, in the probes for capturing KRT14, the concentrations of the probes represented by SEQ ID NO: 148 and SEQ ID NO: 149 are independently 2 to 10 μM, preferably 3 to 8 μM, and more preferably 6 μM;
[0016] Preferably, in the probes for capturing DUOX2, the concentrations of the probes represented by SEQ ID NO: 105 and SEQ ID NO: 107 are independently 2 to 10 μM, preferably 2 to 5 μM, and more preferably 2 to 4 μM;
[0017] Preferably, in the probe for capturing PHIP, the concentrations of the probes shown in SEQ ID NO: 423 and SEQ ID NO: 405 are independently 2 to 10 μM, preferably the concentration of the probe shown in SEQ ID NO: 423 is 5 to 10 μM, more preferably 10 μM; the concentration of the probe shown in SEQ ID NO: 405 is 2 to 5 μM, more preferably 2 to 3 μM;
[0018] Preferably, in the probe for capturing SMN2, the concentration of the probe represented by SEQ ID NO: 337 is 2 to 10 μM, preferably 5 to 10 μM, and more preferably 6 to 10 μM;
[0019] Preferably, in the probe for capturing TUBB2B, the concentrations of the probes shown in SEQ ID NO: 356 and SEQ ID NO: 355 are independently 2 to 10 μM, preferably the concentration of the probe shown in SEQ ID NO: 356 is 2 to 6 μM, more preferably 3 to 5 μM; the concentration of the probe shown in SEQ ID NO: 355 is 2 to 5 μM, more preferably 2 to 3 μM;
[0020] Preferably, in the probe for capturing TPK1, the concentration of the probe shown in SEQ ID NO: 493 is 2 to 10 μM, preferably 2 to 5 μM, and more preferably 2 to 3 μM;
[0021] Preferably, in the probe for capturing TAF2, the concentration of the probe represented by SEQ ID NO: 544 is 2 to 10 μM, preferably 2 to 6 μM, and more preferably 2.5 to 3 μM;
[0022] Preferably, the concentration of other probes is 0.5 to 5 μM, preferably 0.5 to 2 μM, more preferably 0.5 to 1.5 μM, and most preferably 1 μM.
[0023] Preferably, the kit further comprises nucleic acid purification components, library construction and quality control components.
[0024] In one aspect, the present invention provides a method for constructing a DNA library, the method comprising the following steps:
[0025] (1) Genomic DNA is interrupted and repaired to obtain DNA fragments;
[0026] (2) connecting the linker to obtain a connection product;
[0027] (3) First round of PCR amplification;
[0028] (4) hybridization elution, screening the amplified product of step (3) using the above-mentioned probe set or the above-mentioned detection reagent or any of the above-mentioned kits;
[0029] (5) A second round of PCR amplification to prepare the library.
[0030] Preferably, step (2), step (3) and step (5) further include a purification step, preferably magnetic bead purification.
[0031] In one aspect, the present invention provides a DNA library, which is constructed by the method described above.
[0032] On the one hand, the present invention provides the use of the above-mentioned probe set or the above-mentioned detection reagent or any one of the above-mentioned kits in the preparation of a product for screening or detecting mutations in newborn genetic diseases.
[0033] Preferably, the genetic diseases include: galactosemia type IV, phenylketonuria, short-chain acyl-CoA dehydrogenase deficiency, succinate semialdehyde dehydrogenase deficiency, methylmalonic aciduria mut(0), Niemann-Pick disease type B, glycogen storage disease type II, congenital glycosylation disorder type Ia, medium-chain acyl-CoA dehydrogenase deficiency, osteogenesis imperfecta type VII, congenital bilateral absence of the vas deferens, autosomal recessive chronic granulomatous disease type 3, familial autosomal dominant Mediterranean fever, severe combined immunodeficiency type 104, Wilson's disease, on disease, Hartsfield syndrome, reticular pigmented dermatosis, anterior segment abnormalities with or without cataracts, dilated cardiomyopathy type 1X, permanent neonatal diabetes type 1, Chung-Jansen syndrome, autosomal recessive deafness type 59, spinal muscular atrophy, phosphoserine phosphatase deficiency, oculocutaneous albinism type IB, mitochondrial DNA depletion syndrome type 9 (encephalomyopathy with methylmalonic aciduria), autosomal recessive deafness type 4 with enlarged vestibular aqueduct, Fanconi anemia complementation group C, Fan Coni anemia complementation group L type, GM2-gangliosidosis, Tay-Sachs disease, non-classic 21-hydroxylase deficiency hyperandrogenism, congenital 21-hydroxylase deficiency adrenal hyperplasia, autosomal dominant dystrophic epidermolysis bullosa, isolated onychodystrophy, pretibial dystrophic epidermolysis bullosa, transient epidermolysis bullosa neonatorum, Vohwinkel syndrome, autosomal recessive deafness type 1A, palmoplantar keratoderma with deafness, 3-methylcrotonyl-CoA carboxy Chemase 1 deficiency, pseudovaginoperineal scrotal hypospadias, combined pituitary hormone deficiency type 2, glycogen storage disease type Ia, persistent truncus arteriosus, thalassemia, spinal muscular atrophy, thyroid hormone synthesis disorder type 6, thiamine metabolism dysfunction syndrome type 5 (paroxysmal encephalopathy type), complex cortical dysplasia with other brain malformations type 7, Angelman syndrome, autosomal recessive osteopetrosis type 8, T-cell immunodeficiency, recurrent infections, autoimmunity and cardiac malformations, autosomal recessive mental retardation type 40.
[0034] Effects of the Invention
[0035] The present invention is based on high-throughput sequencing technology to select pathogenic genes related to neonatal genetic diseases, optimize the design of gene capture probes, and obtain a panel of pathogenic genes for neonatal genetic diseases. Newborns are screened based on this panel, which can provide an efficient, convenient, rapid and low-cost test with wide coverage, which can be used to indicate the risk of genetic diseases in newborns and assist clinical diagnosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 This is a flow chart for detecting pathogenic genes for neonatal genetic diseases provided by the present invention. DETAILED DESCRIPTION
[0037] In order to make the technical solutions and beneficial effects of the present invention more clearly understandable, the following is a detailed description by listing specific embodiments. The drawings are not necessarily drawn to scale, and local features may be enlarged or reduced to more clearly show the details of the local features; unless otherwise defined, the technical and scientific terms used herein have the same meanings as those in the technical field to which this application belongs.
[0038] After extensive and in-depth research, the inventors first determined the pathogenic genes of neonatal-related genetic diseases of the present invention by searching, for example, using keywords such as newborn, infant, genetic disorder / condition, Icterus and convulsion to search in databases such as OMIM and Pubmed to obtain related genes, a total of 48 high-frequency genes related to neonatal genetic diseases were found.
[0039] On the one hand, the present invention provides a probe set for detecting gene mutations in newborns, which is a probe composition for specifically capturing target gene sequences, and the target genes include one or more of ACADM, SMPD1, TYR, PAH, ACADS, GJB2, ATP7B, UBE3A, DUOX2, HEXA, HBA2, HBA1, MEFV, PMM2, KRT14, G6PC1, GAA, SRD5A2, GALM, FANCL, SUCLG1, PJVK, STK4, NCF4, CRTAP, COL7A1, MCCC1, IL7R, SMN2, SMN1, NKX2-5, PROP1, TUBB2B, ALDH5A1, CYP21A2, MMUT, PHIP, SNX10, GCK, PSPH, SLC26A4, CFTR, TPK1, FGFR1, EYA1, TAF2, FANCC and FKTN. Table 1 shows the gene panel related to newborn genetic disease screening.
[0040] Table 1
[0041]
[0042]
[0043] The schematic diagram of the process of detecting pathogenic genes of neonatal genetic diseases according to the present invention is as follows: Figure 1 As shown, the extracted and purified DNA is first constructed into a pre-library, including enzyme fragmentation, end modification, adapter connection, and PCR amplification. The capture probe is then used to perform a hybrid capture reaction on the pre-library, and streptavidin magnetic beads are used to enrich the captured target region DNA fragments. After quantification and quality control, the captured enriched library is subjected to high-throughput sequencing on the Illumina sequencing platform. The sequencing data is analyzed by bioinformatics software and annotated by genetic interpreters to determine whether there are clinically significant germline mutations in the sample to be tested.
[0044] The design of DNA capture probes is crucial for this detection. Nucleic acid probes are usually designed based on basic parameters of hybridization kinetics and thermodynamics such as GC content, Tm value, etc. The probe design process is: 1) Determine the genomic region that needs to be captured. The region of the present invention is the 48 gene exon regions covered by newborn screening. 2) Target region annotation: Use the gene annotation database (UCSC Genome Browser, Ensembl, NCBI) to obtain the genomic coordinates of the target region. 3) Enter the genomic coordinates into the probe design software, set the probe GC% to 40%~60%, and the Tm to 65℃~75℃. 4) Determine the specificity of the probe sequence through BLAST. 5) Order synthetic probes, verify the capture efficiency and coverage, and optimize the probes based on the results.
[0045] On the one hand, the present invention provides a probe set for detecting gene mutations of common genetic diseases in newborns, wherein the probe set is a probe composition for specifically capturing target gene sequences, and the target genes include one or more of ACADM, SMPD1, TYR, PAH, ACADS, GJB2, ATP7B, UBE3A, DUOX2, HEXA, HBA2, HBA1, MEFV, PMM2, KRT14, G6PC1, GAA, SRD5A2, GALM, FANCL, SUCLG1, PJVK, STK4, NCF4, CRTAP, COL7A1, MCCC1, IL7R, SMN2, SMN1, NKX2-5, PROP1, TUBB2B, ALDH5A1, CYP21A2, MMUT, PHIP, SNX10, GCK, PSPH, SLC26A4, CFTR, TPK1, FGFR1, EYA1, TAF2, FANCC and FKTN.
[0046] The probes designed for the target genes provided by the present invention are shown in Tables 2 to 12, and their nucleotide sequences are shown in SEQ ID NO: 1 to SEQ ID NO: 581.
[0047] Table 2
[0048]
[0049]
[0050]
[0051]
[0052]
[0053] Table 3
[0054]
[0055]
[0056]
[0057]
[0058]
[0059] Table 4
[0060]
[0061]
[0062]
[0063]
[0064] Table 5
[0065]
[0066]
[0067]
[0068] Table 6
[0069]
[0070]
[0071]
[0072]
[0073] Table 7
[0074]
[0075]
[0076]
[0077]
[0078] Table 8
[0079]
[0080]
[0081]
[0082]
[0083] Table 9
[0084]
[0085]
[0086]
[0087]
[0088]
[0089] Table 10
[0090]
[0091]
[0092]
[0093]
[0094]
[0095] Table 11
[0096]
[0097]
[0098]
[0099]
[0100] Table 12
[0101]
[0102]
[0103]
[0104] In certain embodiments, the GC content of each probe in the probe composition is 40% to 60%, for example, 42%, 44%, 46%, 48%, 50%, 52%, 54%, 56%, 58%, 60%, etc.
[0105] In certain embodiments, the annealing temperature of each probe in the probe composition is 65°C to 75°C, for example, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, etc.
[0106] In one aspect, the present invention provides a detection reagent, comprising any one of the probe sets described above.
[0107] On the one hand, the present invention provides a kit for detecting gene mutations of common genetic diseases in newborns, the kit comprising a target gene sequence capture component, and the target gene sequence capture component comprises any one of the probe sets described above.
[0108] Due to the presence of high GC regions, highly repetitive regions and complex genes in the human genome, the capture efficiency of the above target regions is low. Therefore, it is necessary to optimize the specific capture probes for the region / gene to achieve the best capture efficiency. In the detection process of the present invention, the high GC regions, highly repetitive regions and complex genes in the target region are first optimized, such as uneven gene coverage optimization and complex gene probe optimization.
[0109] Complex gene region (HBA1 / HBA2) probe optimization: The α-globin gene cluster includes 4 functional genes and 2 non-functional genes (pseudogenes), arranged in the order of 5'-HBZ-HBZP1-HBAP2-HBAP1-HBA2-HBA1-HBQ1-3. Among them, HBA1 and HBA2 genes contain 3 exon regions with the same coding sequence, and there are differences in the sequences of 5'UTR region, intron and 3'UTR region. Most of the α-thalassemia phenotypes, about 85%, are caused by the deletion of HBA1 and HBA2 genes. Common deletions mainly include 3.7Kb deletions (-α 3.7 )、4.7Kb deletion (-α 4.7 ), Southeast Asian deletion (--α SEA ) and Philippine deletion (-- FIL ). The partial deletion not only includes the HBA1 / HBA2 gene region, but also includes other genes in the α-globin gene cluster. Therefore, it is necessary to design probes for other positions of the entire gene cluster. Therefore, in addition to designing probes for the HBA1 / HBA2 gene region, the present invention also covers the α-globin gene cluster region and some flanking regions such as POLR3K, HS-40, HBZ, HBZP1, HBAP2, HBAP1, HBQ1, LUC7L, ITFGS, RGS11, AXIN1 and DECR2, ensuring comprehensive coverage of the pathogenic variant region that causes the α-thalassemia phenotype.
[0110] In some embodiments, the concentration of each probe in the target gene sequence capture component is independently 0.5-15 μM, for example, 1 μM, 1.5 μM, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM, etc.
[0111] In certain embodiments, among the probes for capturing KRT14, the concentrations of the probes shown in SEQ ID NO: 148 and SEQ ID NO: 149 are each independently 2 to 10 μM, for example, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM, etc.
[0112] In certain embodiments, in the probes for capturing KRT14, the concentrations of the probes represented by SEQ ID NO: 148 and SEQ ID NO: 149 are independently 3 to 8 μM.
[0113] In certain embodiments, in the probes for capturing KRT14, the concentrations of the probes represented by SEQ ID NO: 148 and SEQ ID NO: 149 are each independently 6 μM.
[0114] In certain embodiments, among the probes for capturing DUOX2, the concentrations of the probes shown in SEQ ID NO: 105 and SEQ ID NO: 107 are each independently 2 to 10 μM, for example, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM, etc.
[0115] In certain embodiments, in the probes for capturing DUOX2, the concentrations of the probes shown in SEQ ID NO: 105 and SEQ ID NO: 107 are each independently 2 to 5 μM.
[0116] In certain embodiments, among the probes for capturing DUOX2, the concentrations of the probes represented by SEQ ID NO: 105 and SEQ ID NO: 107 are independently 2 to 4 μM.
[0117] In certain embodiments, the concentration of the probe represented by SEQ ID NO: 105 in the probe for capturing DUOX2 is 2 μM.
[0118] In certain embodiments, the concentration of the probe represented by SEQ ID NO: 107 in the probe for capturing DUOX2 is 3 μM.
[0119] In certain embodiments, in the probe for capturing PHIP, the concentrations of the probes shown in SEQ ID NO: 423 and SEQ ID NO: 405 are each independently 2 to 10 μM, for example, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM, etc.
[0120] In certain embodiments, in the probe for capturing PHIP, the concentration of the probe represented by SEQ ID NO: 423 is 5-10 μM.
[0121] In certain embodiments, in the probe for capturing PHIP, the concentration of the probe represented by SEQ ID NO: 423 is 10 μM.
[0122] In certain embodiments, in the probe for capturing PHIP, the concentration of the probe represented by SEQ ID NO: 405 is 2-5 μM.
[0123] In certain embodiments, in the probe for capturing PHIP, the concentration of the probe represented by SEQ ID NO: 405 is 2-3 μM.
[0124] In certain embodiments, in the probe for capturing PHIP, the concentration of the probe represented by SEQ ID NO: 405 is 2 μM.
[0125] In certain embodiments, in the probe for capturing SMN2, the concentration of the probe shown in SEQ ID NO: 337 is 2 to 10 μM, for example, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM, etc.
[0126] In certain embodiments, in the probe for capturing SMN2, the concentration of the probe represented by SEQ ID NO: 337 is 5 to 10 μM.
[0127] In certain embodiments, in the probe for capturing SMN2, the concentration of the probe shown in SEQ ID NO: 337 is 6 to 10 μM;
[0128] In certain embodiments, the concentration of the probe represented by SEQ ID NO: 337 in the probe for capturing SMN2 is 8 μM.
[0129] In certain embodiments, among the probes for capturing TUBB2B, the concentrations of the probes shown in SEQ ID NO: 356 and SEQ ID NO: 355 are each independently 2 to 10 μM, for example, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM, etc.
[0130] In certain embodiments, in the probe for capturing TUBB2B, the concentration of the probe represented by SEQ ID NO: 356 is 2 to 6 μM.
[0131] In certain embodiments, in the probe for capturing TUBB2B, the concentration of the probe represented by SEQ ID NO: 356 is 3 to 5 μM.
[0132] In certain embodiments, the concentration of the probe represented by SEQ ID NO: 356 in the probe for capturing TUBB2B is 4 μM.
[0133] In certain embodiments, in the probe for capturing TUBB2B, the concentration of the probe represented by SEQ ID NO: 355 is 2 to 5 μM.
[0134] In certain embodiments, in the probe for capturing TUBB2B, the concentration of the probe represented by SEQ ID NO: 355 is 2-3 μM.
[0135] In certain embodiments, the concentration of the probe represented by SEQ ID NO: 355 in the probe for capturing TUBB2B is 2 μM.
[0136] In certain embodiments, in the probe for capturing TPK1, the concentration of the probe shown in SEQ ID NO: 493 is 2 to 10 μM, for example, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM, etc.
[0137] In certain embodiments, in the probe for capturing TPK1, the concentration of the probe represented by SEQ ID NO: 493 is 2 to 5 μM.
[0138] In certain embodiments, in the probe for capturing TPK1, the concentration of the probe represented by SEQ ID NO: 493 is 2-3 μM.
[0139] In certain embodiments, in the probe for capturing TAF2, the concentration of the probe shown in SEQ ID NO: 544 is 2 to 10 μM, for example, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM, etc.
[0140] In certain embodiments, in the probe for capturing TAF2, the concentration of the probe represented by SEQ ID NO: 544 is 2 to 6 μM.
[0141] In certain embodiments, in the probe for capturing TAF2, the concentration of the probe represented by SEQ ID NO: 544 is 2.5-3 μM.
[0142] In certain embodiments, in the probe for capturing TAF2, the concentration of the probe represented by SEQ ID NO: 544 is 2.5 μM.
[0143] In certain embodiments, the concentration of other probes is 0.5-5 μM, for example, 1 μM, 1.5 μM, 2 μM, 2.5 μM, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM.
[0144] In certain embodiments, the concentration of the other probes is 0.5-2 μM.
[0145] In certain embodiments, the concentration of the other probes is 0.5-1.5 μM.
[0146] In certain embodiments, the concentration of the additional probes is 1 μM.
[0147] The present invention is based on high-throughput sequencing technology to select pathogenic genes related to neonatal genetic diseases and optimize the design of gene capture probes to obtain a neonatal genetic disease pathogenic gene panel that can simultaneously detect multiple gene variations, or even simultaneously detect multiple gene variations based on a single hybridization reaction system.
[0148] In certain embodiments, the kit further comprises nucleic acid purification components, library construction and quality control components.
[0149] In one aspect, the present invention provides a method for constructing a DNA library, the method comprising the following steps:
[0150] (1) Genomic DNA is interrupted and repaired to obtain DNA fragments;
[0151] (2) connecting the linker to obtain a connection product;
[0152] (3) First round of PCR amplification;
[0153] (4) hybridization elution, screening the amplified product of step (3) using the above-mentioned probe set or the above-mentioned detection reagent or any of the above-mentioned kits;
[0154] (5) A second round of PCR amplification to prepare the library.
[0155] In certain embodiments, step (2), step (3) and step (5) are followed by a purification step, preferably magnetic bead purification.
[0156] In certain embodiments, the tag sequence is added during the first round of PCR amplification.
[0157] In one aspect, the present invention provides a DNA library, which is constructed by the method described above.
[0158] On the one hand, the present invention provides the use of the above-mentioned probe set or the above-mentioned detection reagent or any one of the above-mentioned kits in the preparation of a product for screening or detecting mutations in newborn genetic diseases.
[0159] In certain embodiments, the genetic diseases include: galactosemia type IV, phenylketonuria, short-chain acyl-CoA dehydrogenase deficiency, succinic semialdehyde dehydrogenase deficiency, methylmalonic aciduria mut(0), Niemann-Pick disease type B, glycogen storage disease type II, congenital glycosylation disorder type Ia, medium-chain acyl-CoA dehydrogenase deficiency, osteogenesis imperfecta type VII, congenital bilateral absence of the vas deferens, autosomal recessive chronic granulomatous disease type 3, familial autosomal dominant Mediterranean fever, severe combined immunodeficiency type 104, Wilson disease, Hartsfield syndrome, reticular pigmented dermatosis, anterior segment abnormalities with or without cataracts, dilated cardiomyopathy type 1X, permanent neonatal diabetes mellitus type 1, Chung-Jansen syndrome, autosomal recessive deafness type 59, spinal muscular atrophy, phosphoserine phosphatase deficiency, oculocutaneous albinism type IB, mitochondrial DNA depletion syndrome type 9 (encephalomyopathy with methylmalonic aciduria), autosomal recessive deafness type 4 with enlarged vestibular aqueduct, Fanconi anemia complementation group C type, Fanconi anemia complementation group L type, GM2-gangliosidosis, Tay-Sachs disease, nonclassical 21-hydroxylase deficiency hyperandrogenism, congenital 21-hydroxylase deficiency adrenal hyperplasia, autosomal dominant dystrophic epidermolysis bullosa, isolated onychodystrophy, pretibial dystrophic epidermolysis bullosa, transient epidermolysis bullosa neonatorum, Vohwinkel syndrome, autosomal recessive deafness type 1A, palmoplantar keratoderma with deafness, 3-methylcrotonyl-CoA Carboxylase 1 deficiency, pseudovaginoperineal scrotal hypospadias, combined pituitary hormone deficiency type 2, glycogen storage disease type Ia, persistent truncus arteriosus, thalassemia, spinal muscular atrophy, thyroid hormone synthesis disorder type 6, thiamine metabolism dysfunction syndrome type 5 (paroxysmal encephalopathy type), complex cortical dysplasia with other brain malformations type 7, Angelman syndrome, autosomal recessive osteopetrosis type 8, T-cell immunodeficiency, recurrent infections, autoimmunity and cardiac malformations, autosomal recessive mental retardation type 40.
[0160] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sam brook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.
[0161] Example 1 Probe Optimization
[0162] Due to differences between sequences of different genes, the capture efficiency under the same probe concentration is different. For some targets, the capture efficiency is low, which ultimately leads to low coverage of sequencing data for the target. Not only does it bring challenges to bioinformatics analysis (for example, for copy number variation detection), it is also possible to reduce the accuracy of detection. Therefore, the uniformity of probe capture needs to be considered in the design process of the probe. As shown in Table 13, in the present invention, for some capture efficiency is poor, the region with poor coverage is encrypted to ensure sequencing coverage uniformity.
[0163] Table 13
[0164]
[0165] The concentration of capture probes for different regions was increased from the original 1 μM to 2-10 μM. Table 13 shows the regions with poor coverage due to capture efficiency. After different degrees of probe optimization were performed on the regions, the average coverage was improved.
[0166] Example 2 Gene mutation screening
[0167] 1. Prelibrary construction: This paper uses commercial library construction reagents (KAPA DNA HyperPrep, KAPABIOSYSTEMS.Inc), purification magnetic beads (VAHTSDNA Clean Beads, Novizan), Illumina universal short linker and linker primers (commissioned to Bioengineering). The specific steps are as follows:
[0168] (1) Purify the prepared 200 ng human genomic DNA using 54 μL of purified magnetic beads and transfer to a 200 μL PCR tube for later use.
[0169] (2) Enzymatic fragmentation:
[0170] Prepare the enzyme digestion working solution according to the following table:
[0171] Reagents Reagent English name Reagent No. Volume (μL / case) 10× fragmentation buffer 10×Frag Buffer FRB 2.5 Fragmentase Frag Enzyme FRE 5 Total enzyme digestion solution - - 7.5
[0172] Use a pistol to draw 7.5 μL of the enzyme digestion working solution and add it to 17.5 μL of the sample purified by magnetic beads. The total volume of the reaction system is 25 μL. Follow the enzyme digestion reaction procedure in the table below:
[0173]
[0174] For high-quality genomic DNA, set the enzyme digestion time according to the following table:
[0175] Target enzyme fragment size 37℃ digestion time Adjustable range 600bp 5min 3-10min 350bp 10min 5-20min 200bp 20min 10-25min 150bp 30min 20-40min
[0176] (3) End repair and A tailing:
[0177] Prepare the "final repair plus A" working solution according to the following table:
[0178] Reagents Reagent English name Reagent No. Volume (μL) / case End repair and A-tailing buffer End Repair & A-Tailing Buffer EAB 3.5 End repair and A-tailing enzyme End Repair&A-Tailing Enzyme Mix EAE 1.5 Total of A working solution added - - 5
[0179] Add 5 μL of "Moxiu Jia A" working solution to the fragmented 25 μL sample, the total volume of the reaction system is 30 μL, and proceed according to the reaction procedure in the table below:
[0180]
[0181] (4) Connector connection:
[0182] Prepare the joint connection working fluid according to the following table:
[0183] Reagents Reagent English name Reagent No. Volume (μL) NF Water NF Water NFW 2 Ligation Buffer Ligation Buffer LGB 15 DNA ligase DNA Ligase DLE 5 Total of joint connection working fluid - - 22
[0184] To each 30 μL sample after the addition of A, add 3 μL Truseq universal short linker (15 μM) and 22 μL linker connection working solution. The total volume of the reaction system is 55 μL. Follow the reaction procedure in the table below and perform magnetic bead purification after connection.
[0185]
[0186] (5) Amplification before hybridization
[0187] The amplification system is shown in the following table:
[0188] Reagents Reagent English name Reagent No. Volume (μL) Purification of product after adapter ligation - - 15 Dual-end index primer mix TS Primer Mix TPM 5 2× High Fidelity Hot Start Master Mix 2×HiFi Hot Start Ready Mix HRM 20 Total volume of reaction system - - 40
[0189] The PCR amplification program is shown in the following table:
[0190]
[0191] The primers are selected to adapt to the sequencing platform adapter, including primers for the Illumina sequencing platform. The PCR amplification products are purified and quality tested using DNA purification magnetic beads to obtain a DNA library for hybridization capture.
[0192] 2. Pre-library hybridization capture reaction: Use the commercial reagent xGen Hybridization and Wash v2kit (INTERGATED DNA TECHNOLOGY), NanoBlockers(for ) and self-designed and optimized capture probes.
[0193] (6) Hybridization reaction
[0194] Prepare hybridization mixture according to the following table:
[0195]
[0196]
[0197] According to the volume of the mixed library and Cot-1 DNA (5 μL), 19 μL of hybridization mixture was added after purification using magnetic beads, and then the supernatant was taken for hybridization reaction procedures (see the table below).
[0198]
[0199] (7) Post-hybridization capture
[0200] 7.1 Prepare 1× eluent according to the following table:
[0201]
[0202] 7.2 Capturing the target fragment
[0203] The equilibrated streptavidin magnetic beads were resuspended in 1× magnetic bead elution buffer and mixed with the liquid obtained after hybridization reaction in the above step (6) (operated on a PCR instrument at 65°C). After thorough mixing, the mixture was reacted at 65°C for 45 minutes.
[0204] The product obtained after the reaction was washed with 1× elution buffer I, 1× stringent elution buffer, 1× elution buffer I, 1× elution buffer II, and 1× elution buffer III, and finally 20 μL of NF water was added, vortexed to mix thoroughly, and then subjected to PCR with magnetic beads after instant centrifugation.
[0205] 7.3 Post-capture amplification
[0206] Prepare the following PCR reaction system:
[0207]
[0208]
[0209] Run the following program on the PCR amplifier:
[0210]
[0211] The PCR amplification products were purified using DNA purification magnetic beads and quality checked (fluorescence quantification instrument Qubit and Agilent2200) to obtain the DNA library.
[0212] 3. Sequencing and analysis
[0213] The obtained sequencing library was sequenced in a sequencer, and the obtained data were subjected to bioinformatics analysis.
[0214] The present application further evaluates the performance of the detection system, as follows: The present invention collects 258 clinical neonatal samples, and compares clinical exon detection with the detection of the neonatal screening panel of the present invention. The detection is performed according to the above detection steps, and the positive samples are shown in the following table:
[0215]
[0216]
[0217]
[0218] The results of the detection method of the present invention and the consistency of the whole exome are as follows:
[0219]
[0220] It can be seen from the above table that the precision (Precision, expressed as the ratio of true positive samples to all predicted positive samples) calculation formula and precision result of the detection panel of the present application are: Precision = TP / (TP+FP) = 44 / (44+0) = 100%; the recall (Recall, expressed as the ratio of predicted true positive samples to all positive samples) calculation formula and recall rate of the detection panel of the present application are: Recall = TP / (TP+FN) = 44 / (44+5) = 89.80%; the F1-score (expressed as the harmonic mean of precision and recall) calculation formula and result of the detection panel of the present application are: F1-score = 2*Precision*Recall / (Precison+Recall) = 1.796 / 1.8980 = 94.62%.
[0221] In summary, the recall rate of neonatal screening in the present invention is 89.80%, and the precision rate is 100%. Among the 5 false negative samples, the genes detected in 5 samples were not included in the detection range of the present invention due to their rarity and late age of onset, considering the input-output ratio. Therefore, in the performance evaluation of the present invention, 5 samples that were not within the detection range were excluded, and the corrected recall rate was 44 / (44+0)=100%. It can be seen from this that the detection kit of the present invention has a high accuracy in screening genes related to neonatal genetic diseases within the detection range.
[0222] It should be understood that the above embodiments are exemplary and are not intended to include all possible implementations included in the claims. Various modifications and changes may be made on the basis of the above embodiments without departing from the scope of the present disclosure. Similarly, the various technical features of the above embodiments may be arbitrarily combined to form other embodiments of the present invention that may not be explicitly described. Therefore, the above embodiments only express several implementations of the present invention and do not limit the scope of protection of the patent of the present invention.
Claims
1. A probe set for detecting gene mutations of common genetic diseases in newborns, characterized in that: The probe set is a probe composition for specifically capturing target gene sequences, and the target genes include one or more of ACADM, SMPD1, TYR, PAH, ACADS, GJB2, ATP7B, UBE3A, DUOX2, HEXA, HBA2, HBA1, MEFV, PMM2, KRT14, G6PC1, GAA, SRD5A2, GALM, FANCL, SUCLG1, PJVK, STK4, NCF4, CRTAP, COL7A1, MCCC1, IL7R, SMN2, SMN1, NKX2-5, PROP1, TUBB2B, ALDH5A1, CYP21A2, MMUT, PHIP, SNX10, GCK, PSPH, SLC26A4, CFTR, TPK1, FGFR1, EYA1, TAF2, FANCC and FKTN.
2. The probe set according to claim 1, characterized in that: The GC content of each probe in the probe composition is 40% to 60%; Preferably, the annealing temperature of each probe in the probe composition is 65°C to 75°C.
3. The probe set according to claim 1 or 2, characterized in that: The nucleotide sequences of the probe composition are shown in SEQ ID NO: 1 to SEQ ID NO:
581.
4. A detection reagent, characterized in that: The detection reagent comprises the probe set according to any one of claims 1 to 3.
5. A kit for detecting gene mutations of common genetic diseases in newborns, characterized in that: The kit comprises a target gene sequence capture component, and the target gene sequence capture component comprises the probe set according to any one of claims 1 to 3.
6. The kit according to claim 5, characterized in that In the target gene sequence capture component, the concentration of each probe is 0.5 to 15 μM, preferably 0.5 to 10 μM; Preferably, in the probes for capturing KRT14, the concentrations of the probes represented by SEQ ID NO: 148 and SEQ ID NO: 149 are independently 2 to 10 μM, preferably 3 to 8 μM, and more preferably 6 μM; Preferably, in the probes for capturing DUOX2, the concentrations of the probes represented by SEQ ID NO: 105 and SEQ ID NO: 107 are independently 2 to 10 μM, preferably 2 to 5 μM, and more preferably 2 to 4 μM; Preferably, in the probe for capturing PHIP, the concentrations of the probes shown in SEQ ID NO: 423 and SEQ ID NO: 405 are independently 2 to 10 μM, preferably the concentration of the probe shown in SEQ ID NO: 423 is 5 to 10 μM, more preferably 10 μM; the concentration of the probe shown in SEQ ID NO: 405 is 2 to 5 μM, more preferably 2 to 3 μM; Preferably, in the probe for capturing SMN2, the concentration of the probe represented by SEQ ID NO: 337 is 2 to 10 μM, preferably 5 to 10 μM, and more preferably 6 to 10 μM; Preferably, in the probe for capturing TUBB2B, the concentrations of the probes shown in SEQ ID NO: 356 and SEQ ID NO: 355 are independently 2 to 10 μM, preferably the concentration of the probe shown in SEQ ID NO: 356 is 2 to 6 μM, more preferably 3 to 5 μM; the concentration of the probe shown in SEQ ID NO: 355 is 2 to 5 μM, more preferably 2 to 3 μM; Preferably, in the probe for capturing TPK1, the concentration of the probe shown in SEQ ID NO: 493 is 2 to 10 μM, preferably 2 to 5 μM, and more preferably 2 to 3 μM; Preferably, in the probe for capturing TAF2, the concentration of the probe represented by SEQ ID NO: 544 is 2 to 10 μM, preferably 2 to 6 μM, and more preferably 2.5 to 3 μM; Preferably, the concentration of other probes is 0.5 to 5 μM, preferably 0.5 to 2 μM, more preferably 0.5 to 1.5 μM, and most preferably 1 μM.
7. The kit according to any one of claims 5 to 6, characterized in that The kit also includes nucleic acid purification components, library construction and quality control components.
8. A method for constructing a DNA library, characterized in that: The method comprises the following steps: (1) Genomic DNA is interrupted and repaired to obtain DNA fragments; (2) connecting the linker to obtain a connection product; (3) First round of PCR amplification; (4) hybridization elution, screening the amplified product of step (3) using the probe set according to any one of claims 1 to 3, the detection reagent according to claim 4, or the kit according to any one of claims 5 to 7; (5) a second round of PCR amplification to prepare the library; Preferably, step (2), step (3) and step (5) further include a purification step, preferably magnetic bead purification.
9. A DNA library constructed by the method according to claim 8.
10. Use of the probe set according to any one of claims 1 to 3, the detection reagent according to claim 4, or the kit according to any one of claims 5 to 7 in the preparation of a product for screening or detecting mutations in genetic diseases in newborns; Preferably, the genetic disease includes: Galactosemia type IV, phenylketonuria, short-chain acyl-CoA dehydrogenase deficiency, succinic semialdehyde dehydrogenase deficiency, methylmalonic aciduria mut(0), Niemann-Pick disease type B, glycogen storage disease type II, congenital glycosylation disorder type Ia, medium-chain acyl-CoA dehydrogenase deficiency, osteogenesis imperfecta type VII, congenital bilateral absence of the vas deferens, autosomal recessive chronic granulomatous disease type 3, familial autosomal dominant Mediterranean fever, severe combined immunodeficiency type 104, Wilson disease, Harts field syndrome, reticular pigmented dermatosis, anterior segment abnormalities with or without cataracts, dilated cardiomyopathy type 1X, permanent neonatal diabetes mellitus type 1, Chung-Jansen syndrome, autosomal recessive deafness type 59, spinal muscular atrophy, phosphoserine phosphatase deficiency, oculocutaneous albinism type IB, mitochondrial DNA depletion syndrome type 9 (encephalomyopathy with methylmalonic aciduria), autosomal recessive deafness type 4 with enlarged vestibular aqueduct, Fanconi anemia complementation group C, Fanconi anemia complementation Group L, GM2-gangliosidosis, Tay-Sachs disease, nonclassical 21-hydroxylase-deficient hyperandrogenism, congenital 21-hydroxylase-deficient adrenal hyperplasia, autosomal dominant dystrophic epidermolysis bullosa, isolated onychodystrophy, pretibial dystrophic epidermolysis bullosa, transient epidermolysis bullosa neonatorum, Vohwinkel syndrome, autosomal recessive deafness type 1A, palmoplantar keratoderma with deafness, 3-methylcrotonyl-CoA carboxylase 1 deficiency, pseudovaginoperineal scrotal hypospadias, combined pituitary hormone deficiency type 2, glycogen storage disease type Ia, persistent truncus arteriosus, thalassemia, spinal muscular atrophy, thyroid hormone synthesis disorder type 6, thiamine metabolism dysfunction syndrome type 5 (paroxysmal encephalopathy type), complex cortical dysplasia with other brain malformations type 7, Angelman syndrome, autosomal recessive osteopetrosis type 8, T-cell immunodeficiency, recurrent infections, autoimmunity and cardiac malformations, autosomal recessive mental retardation type 40.
